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Retrospective comparison of the incidence of acute kidney injury in patients 
treated with intravenous polymyxin B or intravenous colistimethate sodium
Rebecca A. Sumner, Pharm.D.; Jarrod Kile, RPh, BCPS
This study will evaluate and compare the incidence of acute kidney injury 
among patients treated with intravenous polymyxin B and intravenous 
colistimethate sodium.  In a secondary analysis, risk factors that may 
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•  Inclusion Criteria:  
   −  Patients over 18 years of age administered either agent during the 
course of hospital stay for any type of Gram-negative infection.
•  Exclusion Criteria:  
   −  Diagnosis of end-stage renal disease or a dialysis candidate prior 
to therapy initiation, known hypersensitivity to polymyxin B or 
colistimethate sodium, less than 48 hours of polymyxin therapy, previous 
exposure to polymyxin therapy at any point during the specified study 
period and use of inhalational colistimethate sodium monotherapy.
MDPV
Background
•  The polymyxin drug class is effective against Gram-negative bacteria 
including Pseudomonas aeruginosa, Acinetobacter baumannii and 
Klebsiella pneumoniae.  
•  The polymyxins as antimicrobial therapy had previously been replaced by 
more effective, less toxic agents.  The emergence of multidrug-resistant 
bacterium has prompted their utilization in clinical practice.1
•  Colistin is available in two forms, the pro-drug colistimethate sodium and 
its active, more toxic form, colistin sulfate.  Conversion of colistimethate 
sodium to colistin is required for antimicrobial activity since colistimethate 
sodium itself is inactive.  Colistimethate sodium is the only formulation 
currently available in the United States.2   
•  The Risk, Injury, Failure, Loss, End-Stage (RIFLE) criterion defines three 
severity grades for acute kidney injury (risk, injury, failure) and two 
outcomes (loss and end-stage).  Grading of renal dysfunction is classified 
by a change in serum creatinine or glomerular filtration rate.3   
•  The incidence of acute kidney injury with colistimethate sodium is variable, 
ranging from 0%-37%.4 Recent studies utilizing the RIFLE criteria report 
incidences as high as 31%-53.5%.5,6,7
•  The incidence of acute kidney injury associated with polymyxin B ranges 
widely from 6%-54%.4 A recent study reported an incidence of 60% 
through utilization of the RIFLE criteria.8
•  Risk factors for the development of kidney injury with polymyxin 
therapy  may include treatment duration greater than 14 days, higher 
total cumulative drug exposure, use of concomitant nephrotoxic agents 
and presence of co-morbidities including chronic kidney diseae and 
hypertension.
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•  The primary outcome is to compare the incidence of acute kidney 
injury in patients administered intravenous polymyxin B to patients 
administered intravenous colistimethate sodium.  
   −  Acute kidney injury will be defined by use of the RIFLE criteria 
measured by change in serum creatinine.
•  A secondary analysis will be performed based on patient 
demographics in each group to evaluate risk factors that may be 
predictors in the development of acute kidney injury.
•  Patient data to be collected will include:
    −  Age, weight at therapy initiation, gender, APACHE II score and co-
morbid disease states (chronic kidney disease, diabetes mellitus, 
hypertension).
   −  Baseline and serial serum creatinine, actual body weight-based daily 
dose, cumulative dose and duration of treatment.
   −  Use and duration of concomitant nephrotoxic agents (vancomycin, 
aminoglycosides, vasopressors, amphotericin B, angiotensin 
converting enzyme inhibitors, angiotensin receptor blockers, 
calcineurin inhibitors, non-steroidal anti-inflammatory drugs, 
ganciclovir, IV contrast medium).
•  Following data collection, the rate of acute kidney injury in each 
group will be determined and compared for significance utilizing the 
chi-squared test.Retrospective chart review of 150 patients in each group receiving 
intravenous polymyxin B or intravenous colistimethate sodium for at least 48 
hours for all Gram-negative bacterial infections.
Study Design
